Novartis’ TV advert for breast most cancers drug Kisqali attracts untitled letter from FDA

The FDA despatched No­var­tis a rep­ri­mand final week declare­ing “false or mis­lead­ing” in­for­ma­tion in a TV com­mer­cial for metasta­t­ic breast can­cer drug Kisqali. The TV advert with a “Lengthy Reside” tagline, which is now not run­ning, be­gan in 2022 and final aired in Sep­tem­ber 2023, No­var­tis stated.
The com­mer­cial was once de­scribed as con­cern­ing be­motive it will lead MBC pa­tients “to be­lieve that Kisqali has been proven to be extra ef­fec­tive in deal with­ing their con­di­tion and symp­toms (e.g., with re­spect to over­all sur­vival and qual­i­ty of lifestyles) than was once ac­tu­al­ly demon­strat­ed,” ac­twine­ing to the un­ti­tled let­ter from the FDA’s advert­ver­tis­ing watch­canine, the Of­fice of Pre­scrip­tion Drug Professional­mo­tion (OPDP).

Liberate this text in an instant by way of changing into a loose subscriber.
You’ll get get right of entry to to loose articles every month, plus you’ll be able to customise what newsletters get delivered for your inbox every week, together with breaking information.

Author: OpenAI